ERBB2 and breast cancer: This global, double‐blind, phase III study compared PFS among patients receiving abemaciclib plus fulvestrant (n = 446) vs fulvestrant alone (n = 223) in HR+/HER2− advanced BC patients who were aged ≥18 years, whose disease progressed while receiving prior endocrine therapy.